MedTrace Logo

Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects

NCT04580602 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-02-16

No results posted yet for this study

Summary

The goal of this study is to predict and prevent adverse drug events by investigating the impact of genetic variants, demographics, and environmental factors in subjects status post myocardial infarction and percutaneous coronary insertion who have experienced adverse drug events while on P2Y12 inhibitors.

Conditions

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Cipherome, Inc.

    lead INDUSTRY

Principal Investigators

  • Jungwon Suh, MD · SNUBH

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-07
Primary Completion
2022-06-09
Completion
2022-06-09

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04580602 on ClinicalTrials.gov